Alternative Data for Kyverna Therapeutics
| Alternative Data | Value | 3m Change | Trend | Benchmark |
|---|---|---|---|---|
| Job Posts | 9 | Sign up | Sign up | Sign up |
| Sentiment | 100 | Sign up | Sign up | Sign up |
| Webpage traffic | 9,000 | Sign up | Sign up | Sign up |
| Employee Rating | 56 | Sign up | Sign up | Sign up |
| Google Trends | N/A | Sign up | Sign up | Sign up |
| 4chan Mentions | N/A | Sign up | Sign up | Sign up |
| Reddit Mentions | N/A | Sign up | Sign up | Sign up |
| Stocktwits Mentions | 18 | Sign up | Sign up | Sign up |
| Stocktwits Subscribers | 969 | Sign up | Sign up | Sign up |
| X Followers | 323 | Sign up | Sign up | Sign up |
| X Mentions | 12 | Sign up | Sign up | Sign up |
| News Mentions | N/A | Sign up | Sign up | Sign up |
| Customer reviews | N/A | Sign up | Sign up | Sign up |
| Business Outlook | 49 | Sign up | Sign up | Sign up |
| Linkedin Employees | 152 | Sign up | Sign up | Sign up |
About Kyverna Therapeutics
Kyverna Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing cell therapies for patients suffering from autoimmune diseases.
| Price | $7.26 |
| Target Price | Sign up |
| Volume | 583,110 |
| Market Cap | $433M |
| Year Range | $2.55 - $10.82 |
| Dividend Yield | 0% |
| Analyst Rating | 80% buy |
| Industry | Biotechnology |
In the news
Financial performance View All
| Revenue | Cost of Revenue | Gross Profit | Net Income | ebitda | EPS | |
|---|---|---|---|---|---|---|
| Q3 '25 | 0 | 0 | 0 | -37M | -36M | -0.850 |
| Q2 '25 | 0 | 520,000 | -520,000 | -42M | -42M | -0.970 |
| Q1 '25 | 0 | 500,000 | -500,000 | -45M | -44M | -1.030 |
| Q4 '24 | 2M | 560,000 | -560,000 | -37M | -37M | -0.868 |
| Q3 '24 | 0 | 560,000 | -560,000 | -34M | -34M | -0.800 |
Insider Transactions View All
| Westlake BioPartners Fund I, L.P. filed to buy 869,317 shares at $7.5. December 22 '25 |
| SEIDENBERG BETH C filed to buy 869,317 shares at $7.5. December 22 '25 |
| Walker Karen Marie filed to sell 22,636 shares at $12.2. December 17 '25 |
Similar companies
Read more about Kyverna Therapeutics (KYTX) and their ai stock analysis, price prediction, earnings, congress trading, insider transactions, technical analysis, job posts, sentiment, webpage traffic, employee rating, google trends, 4chan mentions, reddit mentions, stocktwits mentions, stocktwits subscribers, x followers, x mentions, news mentions, customer reviews, business outlook & linkedin employees.
FAQ - Kyverna Therapeutics
The Market Cap of Kyverna Therapeutics is $433M.
Currently, the price of one share of Kyverna Therapeutics stock is $7.26.
The KYTX stock price chart above provides a comprehensive visual representation of Kyverna Therapeutics' stock performance over time. Investors can use this chart to identify patterns, trends, and potential support or resistance levels. By examining historical data and recent price movements, investors can make more informed decisions regarding buying, holding, or selling Kyverna Therapeutics shares. Our platform offers an up-to-date KYTX stock price chart, along with technical data analysis and alternative data insights.
As of our latest update, Kyverna Therapeutics (KYTX) does not offer dividends to its shareholders. Investors interested in Kyverna Therapeutics should consider the potential for capital appreciation as the primary return on investment, rather than expecting dividend payouts.
Some of the similar stocks of Kyverna Therapeutics are Amgen, Gilead Sciences, Catalyst Pharmaceuticals, Inovio Pharmaceuticals, and Anavex Life Sciences.
